News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MT Newswires Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Image source: The Motley Fool. DATE Thursday, August 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS CEO - Scott SmithInterim CFO - Paul CampbellChief R&D Officer - Philippe MartinChief Commercial Officer - Corinne Le GoffHead of Capital Markets - Bill Szablewski TAKEAWAYS Revenue -- โฆ
Amneal Pharmaceuticals AMRX enters the second half of 2026 with higher guidance and a broader product pipeline. The company is expanding complex generics, biosimilars and specialty medicines while adjusted earnings and EBITDA improve. The trade-off is clear. Rytary has lost exclusivity, generic pricing remains โฆ
VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year's revenue to be around $14.75 โฆ
In early August 2026, Viatris Inc. reported higher second-quarter and year-to-date revenues, a six-month return to net profitability, raised its 2026 earnings guidance midpoint to US$14.75 billion, completed a US$1.15 billion share repurchase program covering 8.7% of shares, and affirmed a US$0.12 quarterly dividend. โฆ
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Viatris stock has delivered a strong 76.1% return over the past year, and the broader valuation checks still indicate the shares may be โฆ
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Viatris raises 2026 guidance alongside completed buyback and fresh product approval Viatris (VTRS) has given investors a busy early August, pairing raised 2026 revenue guidance โฆ
Wall Streetโs major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P โฆ
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The latest research on Viatris centers on a revised price target of US$22 per share and what that figure implies for investors following โฆ
This article first appeared on GuruFocus. Total Revenues: $3.8 billion in Q2 2026, representing 3.5% operational growth year over year. Adjusted EBITDA: $1.2 billion for the quarter. Adjusted EPS: $0.69 per share. Adjusted Gross Margin: 57.5%, an improvement of nearly 1% versus the prior โฆ
For the quarter ended June 2026, Viatris (VTRS) reported revenue of $3.76 billion, up 4.9% over the same period last year. EPS came in at $0.69, compared to $0.62 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $3.68 โฆ
Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings โฆ
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026 Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street's expectations in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year's revenue to be around $14.75 billion, โฆ
Harrow, Inc. NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYAยฎ (varenicline solution) nasal spray 0.03 mg from โฆ
Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025 Adjusted EBITDA was $1.2 Billion, Up 8% Operationally Compared โฆ
In its upcoming report, Viatris (VTRS) is predicted by Wall Street analysts to post quarterly earnings of $0.62 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $3.68 billion, representing a year-over-year increase of 2.6%. The โฆ
Viatris VTRS, a global healthcare company, is scheduled to report second-quarter 2026 results on Aug. 6, before the opening bell. The Zacks Consensus Estimate for second-quarter revenues is pegged at $3.68 billion, while the same for earnings is pinned at 62 cents per share. โฆ
Image by Jakub Zerdzicki via Unsplash With a market cap of $20.5 billion, Viatris Inc. (VTRS) is a global healthcare company committed to empowering people worldwide to live healthier lives at every stage. With a diverse portfolio spanning generics, established brands, and innovative medicines, โฆ
PITTSBURGH, Aug. 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on August 3, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable โฆ
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Viatris received U.S. FDA approval for its new combined hormonal contraceptive patch, Gwyn Lo. The product is a low dose estrogen contraceptive patch with data โฆ
Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when Viatris (VTRS) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its โฆ
New Patch Will Provide Low-Dose Estrogen Combined Hormonal Contraceptive Option Approval Marks an Important Milestone in Viatris' Efforts to Advance Women's Health PITTSBURGH, July 29, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug โฆ
Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS) The end of the earnings season is always a good time to take a step back and see who shined (and who didn't). Let's take a look at how generic pharmaceuticals stocks fared in Q1, starting with โฆ
3d illustration inflation and deflation graph by Deepadesigns via Shutterstock Canonsburg, Pennsylvania-based Viatris Inc. (VTRS) is a global healthcare company that develops, manufactures, and markets branded medicines, generic drugs, complex generics, biosimilars, and over-the-counter products. Valued at a market cap of $19.8 billion, Viatris โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States